Karl Goossens

Digital

At Veeva Commercial Summit this year, web editor Nicole Raleigh spoke with Karl Goossens, General Manager of OpenData Europe at Veeva Systems.

News

argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.